---
schema_version: "secwatch.filing_event.v1"
accession: "0001815776-26-000035"
form_type: "8-K"
ticker: "LENZ"
cik: "0001815776"
company_name: "LENZ Therapeutics, Inc."
filed_at: "2026-05-11T20:07:49+00:00"
generated_at: "2026-05-11T22:35:28.292559+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# LENZ Therapeutics reports Q1 2026 net loss $41.5M, VIZZ product sales $1.7M

## Summary
- Q1 2026 product sales $1.7M from ~25,000 paid prescriptions, 19% increase over Q4 2025.
- Launched DTC campaign with Sarah Jessica Parker; website traffic up 10x; pilot TV advertising in April 2026.
- Submitted MAA to EMA (March 2026) and MHRA (April 2026) for VIZZ; fourth ex-U.S. partnership with Lunatus in Jan 2026.
- Net loss $41.5M ($1.32/share) vs. $14.6M ($0.53/share) in Q1 2025; cash $258.4M to fund operations to positive cash flow.
- Sales force expanding from 88 to 117 by end of Q2 2026; launched ECP direct sales initiative in April 2026.

## SEC filing metadata
- accession: 0001815776-26-000035
- form_type: 8-K
- ticker: LENZ
- cik: 0001815776
- company_name: LENZ Therapeutics, Inc.
- filed_at: 2026-05-11T20:07:49+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815776/000181577626000035/0001815776-26-000035-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815776/000181577626000035/lenz-20260511.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001815776-26-000035
- JSON: https://secwatch.observer/filing/0001815776-26-000035.json
- Plain text: https://secwatch.observer/filing/0001815776-26-000035.txt

## Key facts
- Earnings Releases
  LENZ Therapeutics, Inc. reported the first quarter ended March 31, 2026 results: net income Net loss for the three months ended March 31, 2026 was $41.5 million, EPS $1.32 per share (basic and diluted).
  - Period: the first quarter ended March 31, 2026
  - Net income: Net loss for the three months ended March 31, 2026 was $41.5 million
  - EPS: $1.32 per share (basic and diluted)
  - Result: reported results
  source text: LENZ Therapeutics, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2026
  evidence_url: https://www.sec.gov/Archives/edgar/data/1815776/000181577626000035/0001815776-26-000035-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.